amgen glp-1 obesity drug market potential 2025 Anti-Obesity Size and YoY Growth Rate, 2026-2033 amgen glp-1 obesity drug market
Description
de Heer, J., Rasmussen, C., Coy, D
& Wilke, R
Kreymann, B., Williams, G., Ghatei, M
It is a sympathomimetic amine that works through norepinephrine release in the central nervous system
Pharmacokinetic studies showed the ITCA 650 could achieve steady-state exenatide concentration within 5 days following implantation, compared to 6-7 weeks for exenatide QW [42]
